Overview
Lobbying Costs
9,999€
Financial year: Jan 2015 - Dec 2015
Lobbyists (Full time equivalent)
0.5 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
0
Lobbying Costs over the years
-
Info
Willem Scholten Consultancy
EU Transparency Register
255298920864-73 First registered on 01 Mar 2016
Goals / Remit
Consultant - Medicines and Controlled Substances, i.e. independent consultant in the area of improving access to controlled medicines and drug control policies.
Main EU files targeted
Policies of the EU Hortizaontal Drugs Group with regards r to EU position taken in the UN Commission on Narcotic Drugs and UNGASS 2016;
Commenting on drug control policies by publishing;
Researching and promoting access to controlled medicines globally;
Consultant for the World Health Organization on controlled substances,.Address
Head Office
Wielsekade 64
Lopik 3411AD
NETHERLANDS -
People
Total lobbyists declared
1
Employment time Lobbyists 50% 1 Lobbyists (Full time equivalent)
0.5
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
None declared
Person in charge of EU relations
Mr Willem Scholten (owner)
Person with legal responsibility
Mr Willem Scholten (owner)
-
Categories
Category
I - Professional consultancies/law firms/self-employed consultants
Subcategory
Self-employed consultants
-
Networking
Affiliation
Koninklijke Nederlandse Maatschappij ter Bevordering van de Pharmacie (KNMP)
International Association for Hospice and Palliative Care (IAHPC)Member organisations
None declared
-
Financial Data
Closed financial year
Jan 2015 - Dec 2015
Lobbying costs for closed financial year
9,999€
Other financial info
None declared
Declared lobby clients
Client Name Amount Grünenthal GmbH 0€ - 9,999€ Jazz Pharmaceuticals Inc. 0€ - 9,999€ Mundipharma (Singapore) 0€ - 9,999€ PinneyAssociates Inc. 0€ - 9,999€ World Health Organization 10,000€ - 24,999€ -
EU Structures
Groups (European Commission)
None
ACC
None
Groups (European Parliament)
None
Communication activities
Former Project Manager, EU FP7 Project Access to Controlled Medicines in Europe (ATOME): analysing drug control policies and legislation in 12 Eastern European countries and drafting policy recommendations for these countries.
Regular speaker at the Societal Impact of Pain conference, held biannually, usually at the EP with sponsorship of MEPs. (next May 2916)
Publications in the J Pain and Pall Care Pharmacother (2016) and EAPC Blog and eHospice Blog(both 3-2016); Adequacy of opioid analgesic consumption (submitted to J Pain & Sympt Manag);
Initiator and Management Team Member of the EU FP7 Atome Project (Access to Opioid Medicines in Europe).Other activities
Expert Member for WHO of the Pompidou Group Expert Committee on legislation on access to treatment of opioid dependence (TDOLEG) (will result in policy guidelines directed at EU and EU Member States.)
Expert of the WOLA/Georgetown University expert group "Examining public health approaches to legalizing cannabis"
Meetings
Meetings
None declared